中华皮肤科杂志 ›› 2011, Vol. 44 ›› Issue (10): 724-726.

• 论著 • 上一篇    下一篇

手术扩大切除联合小剂量干扰素α2b治疗侵袭性皮肤恶性黑素瘤32例

陈晓栋1,顾黎雄2,吴晓琰2,沈聪聪3,丁瑜洁4,姚晓东5   

  1. 1. 南通大学附属医院皮肤科
    2. 南通大学附属医院
    3. 南通大学医学院;南通大学附属医院皮肤科
    4. 江苏省南通市南通大学附属医院医学美容科
    5. 南通大学附属医院皮肤性病科
  • 收稿日期:2011-07-01 修回日期:2011-08-10 出版日期:2011-10-15 发布日期:2011-09-30
  • 通讯作者: 陈晓栋 E-mail:dermatochen@163.com

Wide surgical excision combined with low-dose adjuvant interferon-alpha 2b for the treatment of invasive cutaneous malignant melanoma: 32 case report

Chen Xiao-Dong 2,Xiao-Dong YAO2   

  • Received:2011-07-01 Revised:2011-08-10 Online:2011-10-15 Published:2011-09-30
  • Contact: Chen Xiao-Dong E-mail:dermatochen@163.com

摘要:

目的 回顾性分析手术扩大切除联合小剂量干扰素(IFN)α2b治疗皮肤恶性黑素瘤的疗效。方法 32例皮肤恶性黑素瘤患者经术前检查分期后(Ⅱ期21例、Ⅲ期11例)接受了手术扩大切除,手术范围距离皮损或组织病理取材后瘢痕边界1 ~ 2 cm。手术方法包括:直接切除缝合4例、截指(趾)6例、皮肤游离移植15例、任意皮瓣转移3例和轴型皮瓣转移4例。有区域淋巴结转移行选择性淋巴结摘除者9例,腹股沟淋巴结清扫者2例。术后1周,给予IFN-α2b 300万IU皮下注射每周3次,连续1 ~ 3年。结果 所有患者的切口均甲级愈合。截止到2011年6月,2例患者失访,其余30例患者中,6例随访5年,生存4例,死亡2例(均为ⅢC期);7例随访3 ~ 5年,生存5例,死亡2例(均为ⅢC期);13例随访1 ~ 3年,生存12例,死亡1例(为ⅢB期);4例随访1年内的无1例死亡。现存的25例患者中,8例合并区域淋巴结转移,其中2例为手术后2年内新出现的区域淋巴结转移;8例完成了IFN-α2b治疗3年的疗程,11例已接受了1年以上的治疗,不良反应轻微。结论 手术扩大切除联合小剂量干扰素α2b治疗Ⅱ期和Ⅲ期皮肤恶性黑素瘤,能降低局部复发,患者生存率高。

关键词: 治疗

Abstract:

Objective To retrospectively analyze the therapeutic effect of wide surgical excision combined with low-dose adjuvant interferon-alpha 2b on cutaneous malignant melanoma. Methods A total of 32 patients with cutaneous malignant melanoma received wide surgical excision after preoperative examination and staging. The excisions were performed with a margin measuring 1-2 cm from the visible lesions or biopsy scars. Surgical modalities included direct suture after excision (4 patients), dactylolysis or toe amputation (6 patients), free skin grafting (15 patients), random skin flap transfer (3 patients) and pedicle skin flap transfer (4 patients). Lymph nodes were selectively dissected in 9 patients with regional transfer of lymph nodes, and inguinal lymph nodes were cleared away in 2 patients. One week after the operation, patients received adjuvant therapy with subcutaneous injection of interferon-alpha 2b (3 million IU, thrice per week) for one to three years. Results Preoperative tumor staging revealed 21 cases of cutaneous malignant melanoma at stage Ⅱ, and 11 cases at stage Ⅲ. The excisions healed by the first stage in all the patients. Up to June 2011, 2 patients had been lost to follow up, 5 patients with stage Ⅲ melanoma had died. Survival was observed in all of the 4 patients receiving 1-year follow up, 12 of 13 patients receiving 1-3 year follow up, 5 of 7 patients receiving 3-5 year follow up, and 4 of 6 receiving 5-year follow up. Of the 25 surviving patients, regional lymph node metastasis was observed in 8 patients, which developed within 2 years after the operation in 2 patients. The adjuvant therapy with interferon-alpha 2b lasted 3 years in 8 patients, and more than 1 year in 11 patients. Side effects were mild. Conclusion Wide surgical excision plus low-dose interferon-alpha 2b is effective for the treatment of stage Ⅱ and Ⅲ cutaneous malignant melanoma with lower local recurrence and higher survival rate.

Key words: therapy